Analysts Set Shattuck Labs, Inc. (NASDAQ:STTK) Target Price at $10.50

Shattuck Labs, Inc. (NASDAQ:STTK) has earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $10.50.

Several research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd. Citigroup boosted their target price on shares of Shattuck Labs from $4.00 to $7.00 and gave the company a “neutral” rating in a report on Friday, March 13th. Piper Sandler started coverage on Shattuck Labs in a research report on Wednesday, January 28th. They set an “overweight” rating and a $15.00 target price on the stock. Wedbush raised their price target on Shattuck Labs from $4.00 to $8.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Finally, Wall Street Zen upgraded Shattuck Labs from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in STTK. Orbimed Advisors LLC purchased a new stake in shares of Shattuck Labs in the third quarter worth about $15,072,000. NEXTBio Capital Management LP purchased a new position in Shattuck Labs during the fourth quarter valued at approximately $11,497,000. Price T Rowe Associates Inc. MD bought a new stake in Shattuck Labs during the 4th quarter worth approximately $7,031,000. T. Rowe Price Investment Management Inc. bought a new stake in Shattuck Labs during the 4th quarter worth approximately $4,945,000. Finally, Bank of America Corp DE lifted its stake in Shattuck Labs by 2,968.2% in the 3rd quarter. Bank of America Corp DE now owns 1,131,888 shares of the company’s stock worth $2,705,000 after purchasing an additional 1,094,997 shares in the last quarter. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Stock Performance

Shares of Shattuck Labs stock opened at $6.42 on Friday. The stock has a market capitalization of $459.42 million, a P/E ratio of -8.34 and a beta of 1.28. Shattuck Labs has a 52-week low of $0.69 and a 52-week high of $6.81. The stock’s 50-day simple moving average is $4.93 and its 200 day simple moving average is $3.52.

Shattuck Labs (NASDAQ:STTK) last issued its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). The business had revenue of ($1.00) million for the quarter, compared to the consensus estimate of $0.17 million. Equities research analysts forecast that Shattuck Labs will post -1.48 EPS for the current fiscal year.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.